Management Approach for Spinal Cord Tumors
The management of spinal cord tumors requires prompt diagnosis with MRI as the gold standard, followed by treatment selection based on tumor type, spinal stability, and neurological status, with surgical resection indicated for spinal instability, bony compression causing neurological deficit, and failure of radiotherapy. 1
Diagnostic Approach
Imaging
MRI with contrast enhancement is the gold standard diagnostic tool for spinal masses 1
- Requires both T1 and T2-weighted images
- Full spinal column imaging is recommended when metastatic disease is suspected
- Sensitivity: 0.44-0.93; Specificity: 0.90-0.98
CT myelography may be used when MRI is contraindicated 1
- Sensitivity: 0.71-0.97; Specificity: 0.88-1.00
Plain radiographs are insufficient for diagnosis 1
Timing of Imaging
The urgency of MRI depends on presenting symptoms 2, 1:
- Local back pain only: within 2 weeks
- Unilateral radicular pain: within 1 week
- Progressive unilateral radicular deficit (>7 days): within 48 hours
- Rapidly progressive deficit (<7 days): within 24 hours
- Suspected cord compression: within 12 hours
Classification of Spinal Tumors
Spinal tumors are classified based on their location 3:
- Intradural intramedullary - within the spinal cord (e.g., ependymomas, astrocytomas)
- Intradural extramedullary - outside the cord but within the dura (e.g., meningiomas, schwannomas)
- Extradural - outside the dura (e.g., metastatic tumors, primary bone tumors)
Treatment Selection Algorithm
Primary Treatment Considerations
- Tumor type and radiosensitivity
- Spinal stability
- Neurological status
- Patient's life expectancy
Treatment Options
Surgical Resection
- Spinal instability
- Bony compression causing neurological deficit
- Progressive neurological deficits despite other treatments
- Failure of or progression after radiotherapy
- Obtaining tissue diagnosis in cases of unknown primary
Surgical goals 4:
- For primary tumors: "Enneking-appropriate" margins
- For metastatic disease: Adequate debulking, separation, and stabilization
Radiotherapy
- Primary treatment for radiosensitive tumors (lymphoma, myeloma)
- Adjuvant therapy after incomplete resection
- Palliative treatment for patients with:
- Neurological deficits lasting >48 hours
- Life expectancy <3 months
- Multiple areas of compression
- Inability to tolerate surgery
Corticosteroids
- High-dose dexamethasone before radiotherapy improves ambulation rates (81% vs 63% at 3 months) 2, 1
- Used as a temporizing measure to improve or stabilize neurological function until definitive treatment 5
Systemic Therapy
- Primary treatment for highly chemosensitive tumors (e.g., lymphoma, myeloma) 2
- For recurrent primary spinal cord tumors when reoperation or re-irradiation is not feasible 6
- Limited evidence for epidural metastatic disease 5
Special Considerations by Tumor Type
Primary Spinal Cord Tumors
- Ependymomas: Complete surgical resection is often curative 6
- Astrocytomas: Surgery typically incomplete due to infiltrative nature; adjuvant radiotherapy recommended 6
- Meningiomas/Schwannomas: Complete resection often curative; radiotherapy for malignant variants 6
Metastatic Tumors
- For nonambulatory patients: Surgery followed by radiation therapy maximizes neurological function 5
- For ambulatory patients with stable spine: Consider radiation treatment only 5
- For patients with recurrent disease: Re-irradiation or systemic therapy 2
Prognostic Factors
The most important prognostic factor is pretreatment ambulatory status 1
- Patients who are ambulatory before treatment have better outcomes
- Patients with paralysis either at presentation or after treatment have shorter life expectancy 2
Potential Complications and Pitfalls
- Delayed diagnosis leading to irreversible neurological deficits 1
- Failure to obtain histopathological diagnosis before treatment in cases of unknown primary 1
- Inadequate decompression resulting in persistent symptoms 1
- Overlooking spinal instability in extradural pathologies 1
Early recognition of symptoms and prompt treatment are critical for improving outcomes and minimizing neurological morbidity 6.